ir-world-logo irw-world-logo-bogen
facebook-logo youtubelogo twitterlogo googlepluslogo rsslogo linkedinlogo pinterestlogo xinglong
Medigene AG 19.03.2021

Medigene AG: Change in the Executive Management Board

Planegg/Martinsried (18.03.2021) - 18 March 2021. Dr. Kai Pinkernell, Chief Medical Officer and Chief Development Officer (CMO&CDO) of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will leave the Company's Executive Management Board for personal reasons as of 31 March 2021. Dr. René Goedkoop will assume the role of acting CMO and will be responsible for the continuation of Medigene's clinical projects, primarily driving the finalization of the Phase I part of the ongoing clinical trial with MDG1011 in patients with acute myeloid leukemia or myelodysplastic syndrome. Dr. Goedkoop previously has held several CMO positions in international biopharmaceutical companies such as Sensimed S.A., Lausanne, Switzerland, EryDel S.p.A., Bresso (Milan), Italy, or Pharnext S.A., Paris, France, and has had a lead role already in Medigene's clinical trials as Vice President Clinical Affairs since January 2019. Dr. Pinkernell will continue to support Medigene in an advisory role for six months.

 

Dr. Gerd Zettlmeissl, Chairman of Medigene's Supervisory Board: "Kai served Medigene as Senior Vice President and CMO since February 2016 and became a Member of the Executive Management Board in April 2018. On behalf of the Supervisory Board, I would like to thank Kai for his significant contributions to Medigene."

 

 

Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene, added: "Kai was a valued member of the Executive Management Board and during this time mainly drove our clinical trials and advanced the cell therapy manufacturing processes. We wish him all the best in his future endeavors. At the same time, we are pleased that René is stepping up as acting CMO and assumes responsibility for the ongoing clinical studies, ensuring their smooth continuation. With his broad experience he will also contribute to the successful strategic refocus towards solid tumor indications."

--- end of press release ---

 

About Medigene

 

Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

 

For more information, please visit www.medigene.com

 

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

 

Medigene

Dr. Gary Waanders, Dr. Anna Niedl

Phone: +49 89 2000 3333 01

e-mail: investor@medigene.com

 

LifeSci Advisors

Mary-Ann Chang

Phone: +44 7483 284 853

e-mail: mchang@lifesciadvisors.com

 

(end)

 

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg/Martinsried

country: Germany

contact person: Medigene PR/IR

phone: +49 89 2000 3333 01

e-mail: investor@medigene.com

website: www.medigene.com

 

ISIN(s): DE000A1X3W00 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

 

> Medigene AG, weitere Meldungen...
smallcap-investor-logo
investor-sms-logo
irw-press-logo